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Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients
following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although
promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary
infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left
ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in
all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol
approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection
(≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will
receive intracoronary infusion of BM-MNCs 2–8 days after successful reperfusion for AMI added on top of optimal standard of care. The
control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is
pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to
provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients.
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Introduction
Despite the widespread adoption of mechanical reperfusion for
acute myocardial infarction (AMI) and the use of optimal medi-
cal therapy, the medium-to-long term mortality remains as high
as 7–12%.1–3 Impaired left ventricular ejection fraction (LVEF)
following AMI is a powerful predictor of mortality4 as well as mor-
bidity and increased risk of hospitalization for heart failure.5 These
realities have fuelled the search for novel therapies to improve
cardiac function following AMI. Myocardial regeneration following
bone marrow-derived mononuclear cell (BM-MNC) therapy was
initially demonstrated in a murine model of AMI6 at the begin-
ning of the 21st century. Ever since, there has been an enormous
effort to try and translate this exciting pre-clinical promise into
clinically meaningful benefits for patients. The results of relatively
small phase II clinical trials have been heterogeneous, some showing
improvement in cardiac function and others no effect of cell ther-
apy. This may be due to a number of reasons including the difference
in cell isolation and preparation protocols (different number of
cells and compositions), the timing of the infusion procedure, base-
line ejection fraction, and study design. Importantly, all the studies
have shown relative safety and feasibility of bone marrow aspi-
ration and infusion of cells early after AMI. In fact, meta-analysis
studies have demonstrated a signal towards improved clinical out-
come in patients treated with BM-MNCs, including, importantly,
overall mortality.7,8 The European Society of Cardiology (ESC) task
force on stem cells in cardiac disease comprises some of the key
European trialists (17 members from 11 EU countries) that have
contributed to clinical trials in this area and are leading experts in
this field.9 The ESC Task Force has reached the consensus view
that this therapy needs standardizing and testing in a definitive out-
come endpoint clinical trial. This translated into the design of the
BAMI study, the methods and rationale of which are described
in this paper. The aim of the BAMI pivotal outcome trial is to
demonstrate that intracoronary infusion of bone marrow-derived
progenitor cells is safe and will significantly reduce the time to first
occurrence of all-cause death in patients with reduced LVEF after
successful reperfusion for acute ST-elevation myocardial infarction
(STEMI).
Methods
The full protocol can be found in Appendix S1 in the Supplementary
material online.
Study objectives
The primary endpoint of the BAMI study is time from randomization
to all-cause death. Secondary efficacy endpoints include major adverse
cardiac events—a full list of which is given in Table S1 in the Supple-
mentary material online.
Overview of study flow
The BAMI study is a phase III study with a randomized controlled
open-label design. Approximately 3000 STEMI patients are planned to
be enrolled in 11 European countries with at least 17 sites. ..
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.. Patients with an acute STEMI as defined by the universal definition
of AMI undergoing acute revascularization [i.e. either acute percuta-
neous coronary intervention (PCI) within 24 h of symptom onset or
thrombolysis within 12 h followed by acute PCI within 24 h of symp-
tom onset] will be screened at investigational sites. Further details on
screening is given in the ‘Patient screening and randomization’ section.
For patients assigned to the BM-MNC group, 50 ml bone marrow
will be aspirated under local anaesthesia from the iliac crest. Bone mar-
row will be sent to one of the central cell processing centres without
delay allowing that cell processing can start within 24 h of bone marrow
aspiration. The final investigational medicinal product with BM-MNCs
will be produced and sent back to the investigational site. Intracoro-
nary infusion will be performed no later than 24 h after formulation
of the final product and between 2 and 8 days after successfully reper-
fused ST elevation AMI (summarized in Figure 1). Intracoronary infusion
of BM-MNCs will be performed via conventional percutaneous intra-
coronary intervention techniques using an over-the-wire balloon and
stop-flow method with low pressure balloon inflation.10 Importantly,
peri-procedural anticoagulation must be performed with bivalirudin
and not heparin at all recruiting institutions. Patients in the control
group will not undergo any of the described interventions and will not
receive the BM-MNC therapy. All patients will be treated with opti-
mal post-myocardial infarction pharmacological treatment. Between 9
and 12 months post-primary PCI, dual anti-platelet therapy as per local
practice should be applied.
After hospital discharge, all study patients will return to the clinical
centre for an onsite visit at 30 days. They will then be followed up
by telephone at 3 months after randomization and every 3 months
thereafter until the required number of events has been observed. At
this point, all patients will attend a final site visit at the clinical centre.
However, minimum follow-up is 2 years for each patient, so the final
study visit may be performed later for patients who are in the study for
less than 2 years when the full number of events is observed. Endpoints
will be reported as occurring throughout the follow-up. The defined
cardiovascular efficacy endpoints will be adjudicated by an independent
Clinical Event Committee blinded to the patient treatment allocation.
This ensures a consistent and unbiased adjudication of events across all
investigational sites.
The overall study flow is depicted in Figure 2.
Study population
A total of approximately 3000 male and female patients are planned to
be enrolled in the BAMI study. Enrolment will involve at least 17 sites
in 11 countries. Investigational sites will keep a logbook of all patients
proposed to be included.
Table S2 in the Supplementary material online provides a full list of
the inclusion and exclusion criteria for enrolment in the BAMI trial.
Patient screening and randomization
Patients will be recruited based on the existing medical information
from the pool of AMI patients at the clinical centres. Patients who
had primary PCI performed at clinical centres that are different from
the investigational sites can also be included: interested patients may
be referred for screening to any of the participating study sites
within 2–4 days. Informed consent and assessment of eligibility of
patients with respect to inclusion and exclusion criteria will be done
at the investigational site. Written informed consent must be obtained
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Flow-chart of t2c001 drug substance production. PBS, phosphate-buffered saline.
from patients prior to any study-specific procedure. After consenting,
patients undergo the procedures listed for the screening visit.
After ensuring that a patient meets all other eligibility criteria,
the investigator will perform the echocardiographic examination. The
electronic record of echocardiography will be transferred to the
central Echocardiography Core Laboratory for quantitative analysis.
Patients with LVEF ≤45% will be randomized to control arm (Group
1) or treatment arm (Group 2) in a 1:1 ratio, stratified by country.
Patients with LVEF >45% will not be randomized, but will be classified
as screening failures.
Patients in the BM-MNC treatment group that were randomized
but not treated with BM-MNCs will be replaced. After treatment with
investigational medicinal product, patients who discontinue the study
will not be replaced. Patients in the control group will not be replaced
after randomization.
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.. Study duration for study patients
Each enrolled patient will remain in the study throughout the entire
study duration, with a minimum follow-up of 2 years for each patient.
A study patient’s participation may be terminated early for reasonable
cause, such as the investigator’s medical decision. At any time, the
patient has the right to withdraw consent without a negative impact on
her/his medical treatment. However, the investigators are encouraged
to ask for the patient’s permission for further follow-up telephone
contacts from those whose decision for discontinuation was based on
the need for further outpatient visits.
Duration of the whole study
Patients will be enrolled during a recruitment phase of approximately
3 years. Since minimum study duration for one patient is 2 years, the
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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PaƟents with acute myocardial infarcƟon post primary PCI
Screening phase
N = 3000 eligible AMI paƟents 
2-6 days post primary PCI 
Central reading of echocardiography (EF ≤45%) 
 ->randomisaƟon 1:1 
= day 0 
Group 2: BM-MNC, n= 1500 
Bone marrow aspiraƟon= day 0-6 
Intracoronary infusion of BM-MNCs 
= day 0-6 (depending on transportaƟon 
and cell processing schedule) 2-8 days post 
PCI, and follow-up day 1 post infusion 
Group 1: Control, n= 1500 
No intervenƟon = day 0 
Day 30 ± 7 days: site follow-up 
Month 3: Telephone follow-up 
Day 30 ± 7 days: Site visit follow-up 
Month 3: Telephone follow-up 
Every 3 months: Telephone follow-up 
Following observaƟon of full no. of events: 
End of study visit 
Following observaƟon of full no. of events: 
End of study visit 
Every 3 months: Telephone follow-up 
Figure 2 BAMI study flowchart. AMI, acute myocardial infarction; BM-MNC, bone marrow-derived mononuclear cell; EF, ejection fraction.
overall study duration is approximately 5 years. The Data Monitoring
Committee may terminate the study earlier based on safety concerns
at any time. The sponsor may also terminate the study early for
reasonable cause. Competent authorities/ethics committees retain the
right for premature termination of the study according to applicable
regulations. At an individual study centre, the study may be terminated
early if the work performed is not compliant with Good Clinical
Practice.
Sample size and statistical analysis
This trial is designed as an event-driven trial. The estimated required
number of events is based on the assumptions that there will be
a 12% event (death) rate at 2 years in the control group, which
will be reduced to 9% (25% relative reduction, 1.355 hazard ratio)
in the BM-MNC group. In addition, the study will be designed as a
group-sequential study with one interim analysis performed after 150
deaths have been observed. Early termination will be possible at this
stage if the experimental group shows superiority in comparison to
the control group at a statistical significance level of 1%. However, all
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.. patients recruited must complete a 2 year follow-up, even if the trial
is stopped prematurely. Using an alpha-spending function according to
Lan–DeMets,11 an initial total of 450 events will be required to have
90% statistical power to detect the above treatment effect.
With an accrual period of 3 years, total study duration of 5 years
and an expected drop-out rate of 10% at 2 years, it is estimated that a
total of 3000 patients will be needed to observe the required number
of events during the study period.
The efficacy analyses of this study will be performed on the full
analysis set (FAS), including all randomized patients according to their
randomized treatment. In case of many protocol violations, a per
protocol set (PPS) will be defined excluding patients with serious
protocol violations. Finally, a safety set will be defined, including all
patients who were treated according to their actual treatment, for the
assessment of safety parameters. The primary endpoint of all-cause
mortality will be presented using Kaplan–Meier curves by treatment
group. The curves will be compared using a log-rank test. Statistical
significance will be claimed when the resulting P-value is lower than
0.043. The secondary and safety endpoints will be summarized using
cumulative incidence functions (CIFs), allowing for the competing risk
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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of non-cardiac death in the case of cardiac mortality and for the
competing risk of all-cause death without cardiac hospitalization in
the case of cardiac rehospitalization or non-cardiac hospitalization in
the case of cardiac rehospitalization. Comparison of the CIF between
treatment groups will be done by means of the Pepe–Mori test.
Statistical significance for the secondary endpoints will be assessed at
a significance level of 5%. Primary and secondary endpoints will be
assessed for the FAS and the PPS, if defined.
Discussion
The design of the pivotal BAMI study described above has sev-
eral important considerations. This is the first phase III study of
BM-MNCs in AMI, which is powered with the aim of detecting
a 25% reduction in all-cause mortality. Previous trials have mainly
relied on surrogate markers such as LVEF to judge efficacy. The
results of these trials, listed in Table S3 in the Supplementary mate-
rial online, have been inconsistent with variable or no improve-
ment in left ventricular function. Interestingly, improved clinical
outcomes including mortality and rehospitalization for heart failure
have been seen in long-term follow-up of the REPAIR-AMI study.12
Furthermore, meta-analysis studies have also demonstrated a sig-
nal towards reduced mortality and morbidity following BM-MNC
therapy.7,8 It is also important to remember that dramatic changes
in LVEF were not seen in clinical trials of therapies in patients with
AMI that have subsequently been shown to have significant reduc-
tions in mortality.13 The purpose of the BAMI trial is therefore
to investigate this potential mortality-lowering effect of BM-MNC
therapy in an appropriately powered study.
A randomized design with a control group not undergoing
any planned interventional procedure (i.e. bone marrow aspira-
tion or PCI) was chosen to enable evaluation of the addition
of the study treatment on top of the current best standard of
care for three reasons. First, inclusion of a true placebo group
(‘sham-intervention’) is generally ethically controversial. Second,
the previous double-blind, placebo-controlled, REPAIR-AMI trial
has already documented a beneficial effect of intracoronary admin-
istration of bone marrow-derived progenitor cells on functional left
ventricular contractile recovery post-AMI as well as on long-term
mortality and morbidity.10,12,14 Third, there are small risks associ-
ated with the interventions required for BM-MNC therapy, though
these have been evaluated as acceptable in the risk/benefit assess-
ment for the cell therapy group.
As mentioned previously, the results of previous phase II trials
have been inconsistent with regard to efficacy and potential reasons
for this include heterogeneity in study design and cell isolation pro-
tocols. An important aspect of the BAMI trial has been standard-
ization of the cell processing (using multiple core lab facilities) and
intracoronary infusion techniques. For example, only bivalirudin
is recommended for peri-procedural anticoagulation during infu-
sion, in view of recent data demonstrating impaired migration and
homing function of BM-MNCs exposed to heparin.15 Also, the infu-
sion procedure will be performed within 2–8 days after AMI in all
patients as this appears to be the most efficacious time-point from
meta-analysis.8 The trial has been designed using the intracoro-
nary rather than intramyocardial infusion method based on existing ..
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.. data (Supplementary material online, Table S3) and the concerns of
ventricular perforation using the currently available percutaneous
intramyocardial injection systems at the time of AMI.
Finally, objective unbiased measurement of LVEF in the Echocar-
diography Core Lab after web-based transmission will ensure that
only patients with LVEF ≤45% will be included in order to select
for high-risk survivors of AMI.
The BAMI trial is therefore an ambitious venture but with a
robust study design which addresses the limitations of the previous
smaller phase II trials. Hard clinical outcome data have been lacking
in this field and this trial will for the first time provide an answer
as to whether BM-MNC therapy lowers mortality following AMI.
Conclusions
The pivotal BAMI study will be the largest study of BM-MNCs in
patients with impaired left ventricular systolic function following
successful reperfusion for acute STEMI. The objective of the
trial is simple with a single primary endpoint aiming to detect a
25% reduction in all-cause mortality with BM-MNC therapy. The
results of the BAMI trial will be highly anticipated, as the field of
regenerative therapy will finally have an appropriately sized trial to
provide an answer for the most important clinical outcome of all.
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